Nice prediction from Yahoo board (SoCalDreamer72) : Hello everyone. With all the talk and speculation I figured I would take a stab at predicting INNV's
future pps. Instead of guessing, I looked at other Pharma companies and compared their numbers.
Yes, they are profitable, so will INNV be soon.
.
Celg $124 pps 774,000,000 shares MC 95.6 bill
Yearly rev. 11.229 billion
Pfizer. $33.88 pps. 5.9 billion shares MC 202b. Yearly revenue. 52.8 billion
Gsk $40.9 pps. 420,912,000 shares MC101.6 b
Yearly rev 27.8 billion
CELG revenue is 11.5% of market cap
Pfizers revenue is 26% of market cap
GSK. Revenue is 27% of market cap
This is a small sample, but I will toss CELG out as an outlier for the first number. This means that the average percentage of rev to market cap is 26.5%.
If INNV follows this same model then it will have 75 mill in revenues as stated earlier on this board. If that is 26.5% of market cap as per model then market cap should be 283 million. Dividing 283 million by os pps would be $2.28. That is figured by dividing market cap $283 million by os 124.8 million (per innv website.)
If using CELG as a model it would be $652 million mc and pps of $5.25.
I feel we have good times ahead. p.s. Its better then listen cry from Shawn .............